companies

The administration of United States President Donald Trump is planning to meet with executives from US oil companies later this week to discuss boosting Venezuelan oil production after US forces abducted its leader, Nicolas Maduro, the Reuters news agency has reported, citing unnamed sources.

The meetings are crucial to the administration’s hopes of getting top US oil companies back into the South American nation after its government, nearly two decades ago, took control of US-led energy operations there, the Reuters news agency report said on Monday.

The three biggest US oil companies – Exxon Mobil, ConocoPhillips and Chevron – have not yet had any conversations with the Trump administration about Maduro’s ouster, according to four oil industry executives familiar with the matter, contradicting Trump’s statements over the weekend that he had already held meetings with “all” the US oil companies, both before and since Maduro was abducted.

“Nobody in those three companies has had conversations with the White House about operating in Venezuela, pre-removal or post-removal, to this point,” one of the sources said on Monday.

The upcoming meetings will be crucial to the administration’s hopes to boost crude oil production and exports from Venezuela, a former OPEC nation that sits atop the world’s largest reserves, and whose crude oil can be refined by specially designed US refineries. Achieving that goal will require years of work and billions of dollars of investment, analysts say.

It is unclear what executives will be attending the upcoming meetings, and whether oil companies will be attending individually or collectively.

The White House did not comment on the meetings, but said it believed the US oil industry was ready to flood into Venezuela.

“All of our oil companies are ready and willing to make big investments in Venezuela that will rebuild their oil infrastructure, which was destroyed by the illegitimate Maduro regime,” said White House spokesperson Taylor Rogers.

Exxon, Chevron and ConocoPhillips did not immediately respond to requests for comment from Reuters.

One oil industry executive told Reuters the companies would be reluctant to talk about potential Venezuela operations in group settings with the White House, citing antitrust concerns that limit collective discussions among competitors about investment plans, timing and production levels.

Political risks, low oil prices

US forces on Saturday conducted a raid on Venezuela’s capital, arresting Maduro in the dead of night and sending him back to the US to face narcoterrorism charges.

Hours after Maduro’s abduction, Trump said he expects the biggest US oil companies to spend billions of dollars boosting Venezuela’s oil production, after it dropped to about a third of its peak over the past two decades due to underinvestment and sanctions.

But those plans will be hindered by a lack of infrastructure, along with deep uncertainty over the country’s political future, legal framework and long-term US policy, according to industry analysts.

“While the Trump administration has suggested large US oil companies will go into Venezuela and spend billions to fix infrastructure, we believe political and other risks, along with current relatively low oil prices, could prevent this from happening anytime soon,” wrote Neal Dingmann of William Blair in a note.

Material change to Venezuelan production will take a lot of time and millions of dollars of infrastructure improvement, he said.

And any investment in Venezuelan infrastructure right now would take place in a weakened global energy market. Crude prices in the US are down by 20 percent compared with last year. The price for a barrel of benchmark US crude has not been above $70 since June, and has not touched $80 per barrel since June of 2024.

A barrel of oil cost more than $130 in the leadup to the US housing crisis in 2008.

Chevron is the only US major currently operating in Venezuela’s oil fields.

Exxon and ConocoPhillips, meanwhile, had storied histories in the country before their projects were nationalised nearly two decades ago by former Venezuelan President Hugo Chavez.

Conoco has been seeking billions of dollars in restitution for the takeover of three oil projects in Venezuela under Chavez. Exxon was involved in lengthy arbitration cases against Venezuela after it exited the country in 2007.

Chevron, which exports about 150,000 barrels per day of crude from Venezuela to the US Gulf Coast, meanwhile, has had to carefully manoeuvre with the Trump administration in an effort to maintain its presence in the country in recent years.

A US embargo on Venezuelan oil remained in full effect, Trump has said.

The S&P 500 energy index rose to its highest since March 2025, with heavyweights Exxon Mobil rising by 2.2 percent and Chevron jumping by 5.1 percent.

United States President Donald Trump announced new agreements aimed at lowering prescription drug prices.

On Friday, alongside leaders from Bristol Myers Squibb, Gilead Sciences, and Merck, among other leading pharma giants, the president announced deals that would cut prices on their medications to match that of the developed nation with the lowest price.

“Starting next year, American drug prices will come down fast and furious and will soon be some of the lowest in the developed world,” Trump said.

“This is the biggest thing having to do with drugs in the history of the purchase of drugs.”

Under the deals, each drugmaker will cut prices on some of the drugs sold to the Medicaid programme for low-income people, senior administration officials said, promising “massive savings” on widely used medicines without giving specific figures.

“We were subsidising the entire world. We’re not doing it anymore,” Trump said at a White House news conference, flanked by nine pharma executives.

Mehmet Oz, the director of the Centres for Medicare and Medicaid Service, said Regeneron, Johnson & Johnson, and AbbVie would visit the White House after the holidays for the launch of the government’s TrumpRx website.

US patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.

The details of each deal were not immediately available, but officials said they included agreements to cut cash-pay direct-to-consumer prices of select drugs sold potentially through the TrumpRx.gov website, to launch drugs in the US at prices equal to – not lower than – those in other wealthy nations and to increase manufacturing. In return, companies can receive a three-year exemption from any tariffs.

Drug prices fall

Merck said it will sell its diabetes drugs Januvia, Janumet and Janumet XR – set to face generic competition next year – directly to US consumers at about 70 percent off list prices. If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels.

Enlicitide is one of two Merck drugs expected to receive a speedy review under the FDA’s new, fast-track pathway, the Reuters news agency has previously reported.

Amgen said it will expand its direct-to-patient programme to include migraine drug Aimovig and rheumatoid arthritis medicine Amjevita, offering both at $299 a month – nearly 60 percent and 80 percent below current US list prices.

In July, Trump sent letters to leaders of 17 major pharmaceutical companies, outlining how they should provide so-called most-favoured -nation prices to the US government’s Medicaid health programme for low-income people, and guarantee that new drugs will not be launched at prices above those in other high-income countries.

So far, five companies have struck deals with the administration to rein in prices. They are Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk and EMD Serono, the US division of Germany’s Merck.

A portion of revenues from each company’s foreign sales will also be remitted to the US to offset costs, officials said.

The companies pledged together to invest more than $150bn in the US for R&D and manufacturing, according to officials, although it was unclear whether that included earlier commitments. Several also agreed to donate drug ingredients to the US strategic reserve.

Trump has long focused on the disparity between drug prices in the US and other wealthy countries, which have government-run health systems that negotiate price discounts.

The spectre of tighter price controls by the US government initially spooked investors, but the terms of the deals announced so far have calmed many of those fears.

Analysts have noted that Medicaid, which accounts for only approximately 10 percent of US drug spending, already benefits from substantial price discounts, exceeding 80 percent in some cases.

Dealmakers in 2025 enjoyed a near-record year for mergers and acquisitions, despite a turbulent spring that threatened hopes of a broader revival. So far this year, there were 70 global deals valued at more than $10 billion each, 22 of them in the fourth quarter, according to Dealogic. Total deal value has surpassed $4.8 trillion, up 41% from 2024, though the number of deals fell 6% to 38,395, marking the second-largest year ever behind 2021.

The spike in mega deals reflects a growing focus on scale. “M&A today is all about the mega deals, the race for scale,” said Anu Aiyengar, JPMorgan’s global head of advisory and M&A. There were at least four deals above $50 billion, with two notable bids for Warner Bros. Discovery totaling over $80 billion and Paramount Skydance’s $108 billion hostile offer.

Drivers of Late-Year Rally

A more permissive regulatory environment in the U.S., coupled with a calmer macroeconomic outlook, is encouraging companies to pursue transformative deals. With antitrust scrutiny easing under the Trump administration, boards and executives are seizing opportunities for strategic acquisitions, according to Frank Aquila, partner at Sullivan & Cromwell.

Dealmakers also say valuations are rising, prompting companies to pay higher multiples while expecting their own stocks to maintain relative strength. “Valuations have been bid up and we’ve seen clients be more aggressive in terms of multiples,” said Lazard’s Mark McMaster.

Technology and AI Influence

Technology deals, particularly those tied to artificial intelligence, have played a prominent role. OpenAI raised $40 billion in funding led by SoftBank, and Aligned Data Centers was acquired for $40 billion. Morgan Stanley’s John Collins said companies are pursuing scale to invest in AI-driven changes, both in tech and across other industries.

Cross-Border and Global Trends

Cross-border M&A activity surged in 2025, reaching $1.24 trillion, the highest since 2021. U.S. and UK companies were the most targeted, while U.S., France, and Japan were the most acquisitive. Multinational companies, particularly from Europe and Japan, are investing in the U.S. to capitalize on the world’s largest market. China and Japan are also seeing strong outbound activity, with Japanese deal values boosted by high-profile transactions like OpenAI and Toyota Industries.

Corporate divestitures are rising, up 30% in volume from last year, exemplified by Holcim’s $30 billion spin-off of its North American business, Amrize. Private equity is also regaining momentum, with global buyouts reaching $1.1 trillion, a 51% increase from 2024.

Outlook for 2026

Dealmakers expect the M&A rally to continue into 2026, with $50 billion–$70 billion deals already in the pipeline and a $100 billion tech transaction not ruled out. Analysts see a multi-year run of high-value deals, fueled by scale-seeking corporations, AI-related opportunities, cross-border expansion, and corporate restructuring. While caution remains in politically uncertain markets like the UK, the global appetite for transformative deals appears set to drive another strong year for mergers and acquisitions.

With information from Reuters.